🔴 Protara Therapeutics is trading 5.23% down today after Q2 loss exceeded expectations

Protara Therapeutics is trading 5.23% down now at $3.90 after reporting second-quarter results that missed analyst expectations.

• Q2 loss was $21.7 million, or $0.36 per share, versus the $0.33-per-share consensus estimate, as clinical-development expenses increased
• Management still expects ADVANCED-2 enrollment completion in Q4 2026
• Cash of $161.9 million supports planned operations into 2028